A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509915-10-00

Acronym

209627(DREAMM 13)

Enrollment

Registered

2024-04-12

Start date

2021-07-27

Completion date

2025-10-28

Last updated

2025-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Multiple Myeloma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Greece

None listed

Source: EU CTIS · Data processed: Feb 4, 2026